Journal Watch · British Journal of Pharmacology · 2026

A comprehensive review of anti-colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications.

This review provides a foundation for their future development as novel agents or adjuvants, warranting further translational and clinical studies to validate their efficacy.

Cong K, Xu M, Wu Z et al.British Journal of Pharmacology3 min readPharma relevance 50/100

DOI: 10.1111/bph.70343PMID: 41572487Study type: review / perspective

TL;DR

This review provides a foundation for their future development as novel agents or adjuvants, warranting further translational and clinical studies to validate their efficacy.

Key findings

  • For key alkaloids, specific molecular targets and interaction modes were identified.
  • Furthermore, novel delivery systems were developed to overcome pharmacokinetic limitations.
  • Synergistic effects with conventional chemotherapy were also demonstrated.
  • The multi-target actions of TCM alkaloids position them as ideal candidates for integrative CRC therapy.
  • This review provides a foundation for their future development as novel agents or adjuvants, warranting further translational and clinical studies to validate their efficacy.

What they did

The botanical sources, chemical classification, molecular targets and multi-level anti-tumour mechanisms of TCM alkaloids were analysed. Pharmacokinetic challenges and delivery strategies of key compounds were also evaluated, integrating evidence from cellular, animal and emerging clinical studies. Inhibition of CRC progression was achieved through multiple validated mechanisms. Cell cycle arrest and apoptosis were induced, while metastasis and angiogenesis were suppressed. The tumour microenvironment and gut microbiota were effectively modulated.

Full abstract (original)

Background: Colorectal cancer (CRC) therapy is limited by resistance and toxicity. Traditional Chinese medicine (TCM) alkaloids, with multi-target potential, offer a promising complementary strategy. This review synthesises their anti-CRC mechanisms and therapeutic potential. A systematic literature review was conducted according to established guidelines. Scientific databases including Web of Science were searched using specific keywords such as 'alkaloid', 'colorectal cancer' and 'traditional Chinese medicine'.

What they did: The botanical sources, chemical classification, molecular targets and multi-level anti-tumour mechanisms of TCM alkaloids were analysed. Pharmacokinetic challenges and delivery strategies of key compounds were also evaluated, integrating evidence from cellular, animal and emerging clinical studies. Inhibition of CRC progression was achieved through multiple validated mechanisms. Cell cycle arrest and apoptosis were induced, while metastasis and angiogenesis were suppressed. The tumour microenvironment and gut microbiota were effectively modulated.

Results & conclusions: For key alkaloids, specific molecular targets and interaction modes were identified. Furthermore, novel delivery systems were developed to overcome pharmacokinetic limitations. Synergistic effects with conventional chemotherapy were also demonstrated. The multi-target actions of TCM alkaloids position them as ideal candidates for integrative CRC therapy. This review provides a foundation for their future development as novel agents or adjuvants, warranting further translational and clinical studies to validate their efficacy.

Abstract © the authors / British Journal of Pharmacology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1111/bph.70343 · PubMed 41572487.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking British Journal of Pharmacology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this British Journal of Pharmacology study find?

This review provides a foundation for their future development as novel agents or adjuvants, warranting further translational and clinical studies to validate their efficacy.

What type of study is this?

It is a review / perspective, published in British Journal of Pharmacology in 2026. The botanical sources, chemical classification, molecular targets and multi-level anti-tumour mechanisms of TCM alkaloids were analysed.

Where can I read the original paper?

The original is at the publisher via DOI 10.1111/bph.70343. PubMed ID: 41572487. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Cong K, Xu M, Wu Z et al.. A comprehensive review of anti-colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications.. British Journal of Pharmacology (2026). DOI: 10.1111/bph.70343.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-comprehensive-review-of-anti-colorectal-cancer-alkaloids-from-traditio-h70343/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides